1. ALLA AKTIER
  2. NYHETER
  3. ALLIGATOR BIOSCIENCE

Alligator Bioscience

Nyheter Alligator Bioscience Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Alligator Bioscience to Participate in Upcoming Industry Conferences in October 2023

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives will participate in the following conferences during October 2023:

  • “Aktiedagen i Lund" by Aktiespararna, October 9, Lund
    Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will present the company, its latest developments and upcoming catalysts to investors at 8.25 am/pm CET. More information about the event can be found here (information in Swedish).
  • 6th LSX Nordic Congress, October 10-11, Copenhagen
    Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will take part in the Biotech Plenary panel entitled "Revolutionizing Oncology Drug Discovery: Novel Approaches And Technologies Shaping The Future Of Cancer Treatment" at 2.50 pm CET on October 11. More information about the conference can be found here.

For further information, please contact:

Søren Bregenholt, CEO
E-mail: soren.bregenholt@alligatorbioscience.com
Phone: +46 (0) 46 540 82 00

LifeSci Advisors
Investor Relations
Guillaume van Renterghem
E-mail: gvanrenterghem@lifesciadvisors.com
Phone: +41 (0) 76 735 01 31

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.

Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.

Attachments

Alligator Bioscience to Participate in Upcoming Industry Conferences in October 2023

Datum 2023-10-03, kl 08:00
Källa MFN
Bifogade filer
Alligator Bioscience to Participate in Upcoming Industry Conferences in October 2023